![EMJ Oncology 9 [Supplement 4] 2021 Front Cover](https://www.emjreviews.com/wp-content/uploads/2021/06/EMJ-Oncology-9-Supplement-4-2021-Front-Cover.jpg)
OVARIAN cancer is the seventh most commonly diagnosed malignancy among women worldwide, and the gynaecologic cancer with the worst prognosis and highest mortality. This is because of its resistance to common chemotherapeutic agents, vague and non-specific symptoms, and the lack of effective screening strategies for early detection. However, new research has suggested that poly(ADP-ribose) polymerase (PARP) inhibitors could potentially transform the treatment landscape of advanced ovarian cancer.
Latest articles
All articles
15 Mins
31st
March
Endometrial Cancer Research in 2024
Endometrial cancer is one of the most common gynaecological cancers in high-income countries and, for many years, has been associated…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
5 Mins
29th
October
From Podium into Practice: Working Together to Revolutionise Cancer Care in the Real World
Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
8 Mins
29th
October
Novel Approaches to Treat Glioblastoma Multiforme
Glioblastoma multiforme (GBM), central nervous system (CNS) WHO Grade 4 astrocytoma, is an almost uniformly lethal disease…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.